Journal
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
Volume 25, Issue -, Pages 61-66Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ctro.2020.09.006
Keywords
Non-small cell lung cancer; Sequential chemoradiotherapy; DNA damage repair inhibitor; Platform trial; Continual reassessment method
Funding
- Cancer Research UK [A28890]
- Yorkshire Cancer Research
- NIHR Manchester Biomedical Research Centre
- MRC [MC_PC_12006, MC_UU_00001/6] Funding Source: UKRI
Ask authors/readers for more resources
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. (c) 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ 4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available